SMH
SVA

Sanders Morris Harris’s Sinovac Biotech, Ltd SVA Stock Holding History

Sanders Morris Harris’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,000
Closed – – 324
2022
Q1 		$0 Buy
+2,000
New – ﹤0.01% 364

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $163M AUM 68.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanders Morris Harris's SVA Position: Q2 2022 in Review

Sanders Morris Harris sold out of Sinovac Biotech, Ltd (SVA) in Q2 2022, closing a stake of 2,000 shares.

Sanders Morris Harris first reported a position in SVA in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 31 funds tracked by Wall St. Rank hold SVA as of Q2 2022.

  • Sanders Morris Harris reported no remaining Sinovac Biotech, Ltd position as of Q2 2022 after selling out during the quarter.
  • Sanders Morris Harris sold 2,000 Sinovac Biotech, Ltd shares in Q2 2022.
  • Sanders Morris Harris first reported a position in Sinovac Biotech, Ltd in Q1 2022 and held it in 1 quarter.
  • Sanders Morris Harris's Sinovac Biotech, Ltd position peaked at $0 in Q1 2022.
  • 31 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2022.

Based on Sanders Morris Harris's 13F filing for Q2 2022, filed 11 Jul 2022.